Market Overview:
Pleural diseases are conditions that affect the pleura, the thin membranes surrounding the lungs. Common pleural diseases include pleurisy, pneumothorax and pleural effusions. Diagnosis and treatment of these conditions involves imaging tests, drainage and medication to relieve pain and eliminate fluid build up in the pleural space. The rising adoption of telehealth services is enabling faster diagnosis and treatment of pleural diseases remotely, driving the growth of this market.

Market key trends:
One of the key trends in the pleural diseases market is the increasing adoption of telehealth services. Telehealth allows patients to visit doctors and receive treatment virtually through video calls, remote monitoring devices and mobile health applications. This is proving highly beneficial for diagnosis and management of pleural diseases without requiring in-person visits. It provides increased access to healthcare in rural or remote areas. The trend of telehealth is expected to grow further over the forecast period as technology advances and its benefits become more widely recognized. This will likely fuel the overall growth of the pleural diseases market.

Segment Analysis
The Pleural Diseases market is dominated by the malignant pleural mesothelioma sub-segment. Malignant pleural mesothelioma accounts for around 30% of the total pleural diseases market share owing to its increasing prevalence due to past asbestos exposure. Mesothelioma starts in the pleura - the thin layer of tissue that covers the lungs and lines the inside of the chest wall and diaphragm. Prolonged exposure to asbestos fibers increases the risks of developing mesothelioma.

Key Takeaways
The Global Pleural Diseases Market Demand is expected to witness high growth, exhibiting CAGR of 6.8% over the forecast period, due to increasing incidence of malignant mesothelioma caused by rising asbestos exposure in previous decades.

Regional analysis
North America dominates the pleural diseases market, with the largest market share of approximately 35% in 2023. The high prevalence of asbestos-related diseases such as mesothelioma in the US contributes to North America's leading position in the market.

Key players
Key players operating in the Pleural Diseases market are Johnson & Johnson, AstraZeneca, Novartis International AG, Roche Holding AG, Bristol Myers Squibb, Merck & Co. Inc., Pfizer Inc., GlaxoSmithKline plc, Boehringer Ingelheim International GmbH, Sanofi, AbbVie Inc., Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Bayer AG, Celgene Corporation.

Read More:

https://perfectinsights.blogspot.com/2023/11/pleural-diseases-market-owing-to-rising.html